Publications
Detailed Information
Bismuth-Containing Quadruple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Byoung Hwan | - |
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Hwang, Tae Jun | - |
dc.contributor.author | Lee, Sang Hyub | - |
dc.contributor.author | Hwang, Jin-Hyeok | - |
dc.contributor.author | Jeong, Sook-Hyang | - |
dc.contributor.author | Jung, Hyun Chae | - |
dc.contributor.author | Song, In Sung | - |
dc.contributor.author | Lee, Dong Hoo | - |
dc.contributor.author | Kim, Jin-Wook | - |
dc.contributor.author | Park, Young Soo | - |
dc.date.accessioned | 2012-05-29T05:58:53Z | - |
dc.date.available | 2012-05-29T05:58:53Z | - |
dc.date.issued | 2010-02 | - |
dc.identifier.citation | HELICOBACTER; Vol.15 1; 38-45 | ko_KR |
dc.identifier.issn | 1083-4389 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76543 | - |
dc.description.abstract | Background: The eradication rate of first-line Helicobacter pylori treatment is only 70-85% and has been decreasing due to the increase in antibiotic resistance. The aim of this study was to evaluate the efficacy of bismuth-containing quadruple therapy as second-line treatment for H. pylori infection based on treatment duration. Methods: We prospectively enrolled 227 patients that were found to have persistent H. pylori infection after first-line proton-pump inhibitor-clarithromycin-amoxicillin triple therapy. Patients were randomized to 1-week (112 patients) and 2-week (115 patients) quadruple therapy with tripotassium dicitrate bismuthate 300 mg q.i.d., meteronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. and esomeprazole 20 mg b.i.d. The eradication rate, drug compliance, and adverse events were compared based on treatment duration. Results: The eradication rates were 72/112 (64.3%, 95% CI: 0.504-0.830) and 71/92 (77.2%, 0.440-0.749) with 1-week group, and 95/115 (82.6%, 1.165-2.449) an 88/94 (93.6%, 1.213-5.113) with 2-week group by intention-to-treat therapy (p = .002) and per-protocol analysis (p = .001), respectively. The adverse events increased as the treatment durations increased from 7 to 14 days (20.0 and 42.5%, respectively, p < .001). However, there was no significant difference in the patient compliance or the rate of major adverse events between the 1- and 2-week groups (6.3 and 12.5%, respectively, p = .133). Conclusion: Two-week bismuth-containing quadruple therapy was more effective than the 1-week treatment, and should be considered for second-line treatment in Korea. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | Helicobacter pylori | ko_KR |
dc.subject | eradication | ko_KR |
dc.subject | resistance | ko_KR |
dc.subject | second-line | ko_KR |
dc.subject | quadruple therapy | ko_KR |
dc.title | Bismuth-Containing Quadruple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이병환 | - |
dc.contributor.AlternativeAuthor | 김나영 | - |
dc.contributor.AlternativeAuthor | 황태준 | - |
dc.contributor.AlternativeAuthor | 이상협 | - |
dc.contributor.AlternativeAuthor | 박영수 | - |
dc.contributor.AlternativeAuthor | 황진혁 | - |
dc.contributor.AlternativeAuthor | 김진욱 | - |
dc.contributor.AlternativeAuthor | 정숙향 | - |
dc.contributor.AlternativeAuthor | 이동호 | - |
dc.contributor.AlternativeAuthor | 정현채 | - |
dc.contributor.AlternativeAuthor | 송인성 | - |
dc.citation.journaltitle | HELICOBACTER | - |
dc.description.citedreference | Yoon H, 2009, HELICOBACTER, V14, P77 | - |
dc.description.citedreference | Kim YS, 2009, EUR J GASTROEN HEPAT, V21, P522, DOI 10.1097/MEG.0b013e3283196af0 | - |
dc.description.citedreference | Hung KH, 2009, HELICOBACTER, V14, P61, DOI 10.1111/j.1523-5378.2009.00655.x | - |
dc.description.citedreference | Kanizaj TF, 2009, HELICOBACTER, V14, P29, DOI 10.1111/j.1523-5378.2009.00656.x | - |
dc.description.citedreference | Rokkas T, 2009, AM J GASTROENTEROL, V104, P21, DOI 10.1038/ajg.2008.87 | - |
dc.description.citedreference | Vakil N, 2009, AM J GASTROENTEROL, V104, P26, DOI 10.1038/ajg.2008.91 | - |
dc.description.citedreference | Kim N, 2008, HELICOBACTER, V13, P245, DOI 10.1111/j.1523-5378.2008.00604.x | - |
dc.description.citedreference | Graham DY, 2008, NAT CLIN PRACT GASTR, V5, P321, DOI 10.1038/ncpgasthep1138 | - |
dc.description.citedreference | HONG EJ, 2008, KOREAN J GASTROENTER, V52, P80 | - |
dc.description.citedreference | Choi HS, 2007, HELICOBACTER, V12, P638 | - |
dc.description.citedreference | Kang JM, 2007, HELICOBACTER, V12, P623 | - |
dc.description.citedreference | Yim JY, 2007, HELICOBACTER, V12, P333 | - |
dc.description.citedreference | Malfertheiner P, 2007, GUT, V56, P772, DOI 10.1136/gut.2006.101634 | - |
dc.description.citedreference | Chung SJ, 2007, HEPATO-GASTROENTEROL, V54, P1293 | - |
dc.description.citedreference | Megraud F, 2007, CLIN MICROBIOL REV, V20, P280, DOI 10.1128/CMR.00033-06 | - |
dc.description.citedreference | BANG SY, 2007, KOREAN J GASTROENTER, V50, P356 | - |
dc.description.citedreference | Kim N, 2006, J CLIN GASTROENTEROL, V40, P683 | - |
dc.description.citedreference | KIM JM, 2006, KOREAN J GASTROENTER, V47, P337 | - |
dc.description.citedreference | CHOUNG RS, 2006, KOREAN J GASTROENTER, V47, P131 | - |
dc.description.citedreference | Di Mario F, 2006, DIGEST DIS, V24, P113, DOI 10.1159/000090315 | - |
dc.description.citedreference | Huang JQ, 2005, WORLD J GASTROENTERO, V11, P2726 | - |
dc.description.citedreference | LEE JH, 2005, KOREAN J GASTROENTER, V46, P94 | - |
dc.description.citedreference | Fischbach LA, 2004, ALIMENT PHARM THERAP, V20, P1071, DOI 10.1111/j.1365-2036.2004.02248.x | - |
dc.description.citedreference | Parente F, 2003, DIGEST LIVER DIS, V35, P523, DOI 10.1016/S1590-8658(03)00268-8 | - |
dc.description.citedreference | Eun CS, 2003, J GASTROENTEROL, V38, P436, DOI 10.1007/s00535-002-1079-2 | - |
dc.description.citedreference | Bago J, 2002, WIEN KLIN WOCHENSCHR, V114, P448 | - |
dc.description.citedreference | Gisbert JP, 2002, ALIMENT PHARM THERAP, V16, P1047 | - |
dc.description.citedreference | Malfertheiner P, 2002, ALIMENT PHARM THERAP, V16, P167 | - |
dc.description.citedreference | de Boer WA, 2001, EUR J GASTROEN HEPAT, V13, P1281 | - |
dc.description.citedreference | Diez JMB, 2000, MED CLIN-BARCELONA, V115, P617 | - |
dc.description.citedreference | Michopoulos S, 2000, ALIMENT PHARM THERAP, V14, P737 | - |
dc.description.citedreference | PARK MJ, 2000, KOREAN J GASTROENTER, V36, P457 | - |
dc.description.citedreference | Laheij RJF, 1999, ALIMENT PHARM THERAP, V13, P857 | - |
dc.description.citedreference | de Boer WA, 1999, EUR J GASTROEN HEPAT, V11, P697 | - |
dc.description.citedreference | van Doorn LJ, 1999, GASTROENTEROLOGY, V116, P823 | - |
dc.description.citedreference | *KOR H PYL STUD GR, 1998, KOREAN J GASTROENTER, V32, P275 | - |
dc.description.citedreference | de Boer WA, 1998, NETH J MED, V52, P10 | - |
dc.description.citedreference | Malfertheiner P, 1997, GUT, V41, P8 | - |
dc.description.citedreference | Axon A, 1997, BRIT MED J, V314, P1430 | - |
dc.description.citedreference | LAM SK, 1997, J GASTROEN HEPATOL, V13, P1 | - |
dc.description.citedreference | DEBOER WA, 1996, HELICOBACTER, V1, P145 | - |
dc.description.citedreference | DEBOER W, 1995, LANCET, V345, P817 | - |
dc.description.citedreference | DEBOER WA, 1994, AM J GASTROENTEROL, V89, P1993 | - |
dc.description.citedreference | NWOKOLO CU, 1992, GASTROENTEROLOGY, V102, P163 | - |
dc.description.tc | 11 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.